Pelvic stereotactic ablative body radiotherapy (SABR) reirradiation: UK SABR consortium guidance for use in routine clinical care.
No Thumbnail Available
All Authors
Moreno-Olmedo, E.
Owczarczyk, K.
Chadwick, E.
Dickinson, P.
Duffton, A.
Jones, B.
Good, JS.
McDonald, F.
Murray, LJ.
Rackley, T.
LTHT Author
Dickinson, Peter
Murray, Anthony
Murray, Anthony
LTHT Department
Oncology
Leeds Cancer Centre
Medical Physics & Engineering
Leeds Cancer Centre
Medical Physics & Engineering
Non Medic
Clinical Scientist
Publication Date
2025
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
Stereotactic ablative body radiotherapy (SABR) is routinely used for the management of oligometastatic disease. Increasingly, there is overlap of targets or organs at risk with previous radiotherapy fields. As substantial variation in delivery of clinical practice exists, the UK SABR Consortium worked with a collaborative national group to develop pelvic SABR re-irradiation consensus guidelines. The scope of the guidance includes patient selection criteria, pre-treatment considerations, delineation guidelines, dose prescription, calculations of cumulative dose constraints, and optimal planning technique. This guidance is part of an ongoing national prospective audit in collaboration with the Royal College of Radiologists and EORTC ReCare.
Journal
Technical Innovations and Patient Support in Radiation Oncology